



BIODLINK INTERNATIONAL COMPANY LIMITED

(incorporated in the Hong Kong with limited liability)

(Stock Code: 1875)

12 February 2026

To the Shareholders and the Option Holders:

Dear Sir or Madam,

**VOLUNTARY CONDITIONAL CASH OFFERS BY
CITIGROUP GLOBAL MARKETS ASIA LIMITED
FOR AND ON BEHALF OF THE OFFEROR
FOR ALL THE ISSUED SHARES OF THE COMPANY
(OTHER THAN THOSE SHARES ALREADY OWNED OR
AGREED TO BE ACQUIRED BY THE OFFEROR AND
THE OFFEROR CONCERT PARTIES) AND
TO CANCEL ALL OUTSTANDING SHARE OPTIONS**

INTRODUCTION

We refer to the Composite Document dated 12 February 2026 in respect of the Offers jointly issued by the Offeror and the Company, of which this letter forms part. Unless the context otherwise requires, capitalised terms used in this letter shall have the same meanings as defined in the Composite Document.

We have been appointed by the Board as members of the Independent Board Committee to consider, among other things, the terms of the Offers and to make a recommendation as to whether, in our opinion, the Offers are fair and reasonable insofar as the Shareholders and the Option Holders are concerned, and as to the acceptance of the Offers.

Grand Moore has been appointed as the Independent Financial Adviser with our approval to advise and make recommendations in respect of the terms of the Offers and as to acceptance of the Offers. Details of its advice and recommendations and the principal factors and reasons which it has considered before arriving at such recommendations, are set out in the section headed "Letter from the Independent Financial Adviser" in the Composite Document.

We also wish to draw your attention to the "Letter from the Board", the "Letter from Citi" and the additional information set out in the appendices to this Composite Document and the accompanying Form(s) of Acceptance in respect of the Offers and the acceptance and settlement procedures for the Offers.

We, as members of the Independent Board Committee, have declared that we are independent and do not have any conflict of interest in respect of the Offers and are therefore able to consider the terms of the Offers and make recommendations accordingly to the Shareholders and the Option Holders. Dr. Weidong LIU, the non-executive Director, is also the managing director of Vivo Capital and was involved in the discussion and/or negotiation of the terms and conditions of the Offers. To avoid any possible conflict of interest, Dr. Weidong LIU is not part of the Independent Board Committee.

RECOMMENDATIONS

The Shareholders and the Option Holders are recommended to read the full text of the “Letter from the Independent Financial Adviser” set out in this Composite Document.

In the letter from the Independent Financial Adviser set out in the section headed “Letter from the Independent Financial Adviser” of this Composite Document, the Independent Financial Adviser states that it is of the opinion that: (i) the Share Offer is fair and reasonable so far as the Shareholders are concerned; and (ii) the Option Offer is fair and reasonable so far as the Option Holders are concerned, and recommends the Independent Board Committee to advise the Shareholders to accept the Share Offer and the Option Holders to accept the Option Offer.


The Independent Board Committee, having considered the terms of the Offers, and having taken into account the advice and recommendation from the Independent Financial Adviser, and in particular the principal factors, reasons and recommendations set out in its letter, considers that the terms of the Offers are fair and reasonable so far as the Shareholders and the Option Holders are concerned. Accordingly, we recommend that the Shareholders accept the Share Offer and the Option Holders accept the Option Offer.

Notwithstanding our recommendations, the Shareholders and the Option Holders should consider carefully the terms of the Offers. In any case, the Shareholders and the Option Holders are reminded that the decision to realise or to hold their investment is subject to individual circumstances and investment objectives.

The Shareholders and Option Holders should note that there is no certainty that the current trading volume and/or current trading price level of the Shares will be sustainable during or after the Offer Period. The Shareholders and the Option Holders should closely monitor the market trading price and liquidity of the Shares during the Offer Period, as well as the business development of the Group and the intentions of the Offeror when there is more information available in this regard.

If in doubt, the Shareholders and the Option Holders should consult their own professional advisers for professional advice. In addition, the Shareholders and the Option Holders who wish to accept the Offers are recommended to read and consider carefully the procedures for accepting the Offers detailed in “Appendix I — Further Terms and Procedures for Acceptance of the Offers” to this Composite Document and the accompanying Form(s) of Acceptance.

Yours faithfully,
For and on behalf of the
Independent Board Committee of
BioDlink International Company Limited



Ms. Hui SUN

*Independent Non-
executive Director*


Mr. Qing ZHANG

*Independent Non-
executive Director*

Dr. Xuelin GU

*Independent Non-
executive Director*

Yours faithfully,
For and on behalf of the
Independent Board Committee of
BioDlink International Company Limited



Ms. Hui SUN
*Independent Non-
executive Director*

Mr. Qing ZHANG
*Independent Non-
executive Director*

Dr. Xuelin GU
*Independent Non-
executive Director*

Yours faithfully,
For and on behalf of the
Independent Board Committee of
BioDlink International Company Limited



Ms. Hui SUN	Mr. Qing ZHANG	Dr. Xuelin GU
<i>Independent Non-executive Director</i>	<i>Independent Non-executive Director</i>	<i>Independent Non-executive Director</i>